GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArriVent BioPharma Inc (NAS:AVBP) » Definitions » Capital Expenditure

ArriVent BioPharma (ArriVent BioPharma) Capital Expenditure : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is ArriVent BioPharma Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

ArriVent BioPharma's cash flow for capital expenditures for the three months ended in Mar. 2024 was $0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

ArriVent BioPharma Capital Expenditure Historical Data

The historical data trend for ArriVent BioPharma's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArriVent BioPharma Capital Expenditure Chart

ArriVent BioPharma Annual Data
Trend Dec21 Dec22 Dec23
Capital Expenditure
- - -

ArriVent BioPharma Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only - - - - -

ArriVent BioPharma Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ArriVent BioPharma (ArriVent BioPharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArriVent BioPharma Inc (NAS:AVBP) » Definitions » Capital Expenditure
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. They seek to utilize our team's deep drug development experience to maximize the potential of our lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

ArriVent BioPharma (ArriVent BioPharma) Headlines

From GuruFocus

ArriVent Appoints Kristine Peterson to its Board of Directors

By Marketwired • 04-22-2024